# EDGAR Filing Document

**Accession Number:** 0001768946
**File Stem:** 0001104659-26-074366
**Filing Date:** 2026-6
**Character Count:** 5046
**Document Hash:** af49c4b7f0dbfdbff017582d7174de12
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-074366.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001104659-26-074366

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260616

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biophytis SA
- **CENTRAL INDEX KEY:** 0001768946
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** I0

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38974
- **FILM NUMBER:** 261093106

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SORBONNE UNIVERSITY, BC 9
- **STREET 2:** BATIMENT A 4EME ETAGE, 4 PLACE JUSSIEU
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0
- **ZIP:** 75001
- **BUSINESS PHONE:** 33 1 44 37 23 00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SORBONNE UNIVERSITY, BC 9
- **STREET 2:** BATIMENT A 4EME ETAGE, 4 PLACE JUSSIEU
- **CITY:** PARIS
- **PROVINCE COUNTRY:** I0
- **ZIP:** 75001

**UNITED STATES SECURITIES**

**AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report: June 16, 2026**

**Commission File Number: 001-38974**

**BIOPHYTIS S.A.**

**(Translation of registrant's name into English)**

**Stanislas Veillet<br> Biophytis S.A.**

**Sorbonne University—BC 9, Bâtiment A 4ème étage**

**4 place Jussieu**

**75005 Paris, France**

**+33 1 44 27 23 00**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

⌧ Form 20-F ◻ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ◻

On June 15, 2026, Biophytis S.A. issued a press release announcing the temporary suspension of the trading of its shares. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

**EXHIBIT LIST**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| [**<u>99.1</u>**](tm2618064d1_ex99-1.htm) | [**<u>Press Release dated June 15, 2026.</u>**](tm2618064d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BIOPHYTIS S.A.** | **BIOPHYTIS S.A.** |
| **Date: June 16, 2026** | By: | /s/ Stanislas Veillet |
|  |  | Name: Stanislas Veillet |
|  |  | Title: Chairman and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1** 

**BIOPHYTIS ANNOUNCES THE TEMPORARY** 

**SUSPENSION OF THE TRADING OF ITS SHARES**

**Paris (France) and Cambridge (Massachusetts, U.S.), June 15, 2026, at 11:00 p.m CET.** – Biophytis SA (Euronext Growth Paris: ALBPS), ("***Biophytis***" or the "***Company***"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, announces the temporary suspension of the trading of its shares by Euronext.

This suspension results from the non-publication of the annual financial report for the fiscal year ended December 31, 2025, due to an operational delay in the preparation of the financial statements. The report will be published following certification of the accounts by the statutory auditors, which is expected no later than the end of July 2026.

Trading of Biophytis shares on Euronext Growth Paris was suspended on June 15, 2026, and is expected to resume following the publication of the annual financial report. The Company will keep the market informed of the date on which trading will resume.

\* \* \*

**<u>About Biophytis</u>**

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age- related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit <u>www.biophytis.com</u>.

**<u>Biophytis Contact</u>**

<u>Investor relations</u>

<u>investors@biophytis.com</u>

<u>Media relations</u>

Antoine Denry: <u>antoine.denry@taddeo.fr</u> – +33 6 18 07 83 27

Nizar Berrada: <u>nizar.berrada@taddeo.fr</u> – +33 6 38 31 90 50